| License: Creative Commons Attribution 4.0 PDF - Published Version (4MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-444280
- DOI to cite this document:
- 10.5283/epub.44428
Abstract
Rho-associated protein kinase (ROCK) inhibitors allow for causative glaucoma therapy. Unfortunately, topically applied ROCK inhibitors suffer from high incidence of hyperemia and low intraocular bioavailability. Therefore, we propose the use of poly (lactide-co-glycolide) (PLGA) microspheres as a depot formulation for intravitreal injection to supply outflow tissues with the ROCK inhibitor ...

Owner only: item control page